In November, FDA posted three notable Form 483s to sites of Aurobindo, one of which is a substantial 37 pages. Zydus Cadila received a 23-page, 14-observation Form 483 based on an inspection performed by FDA investigators Thomas Arista and Justin Boyd.

[NOTE: Are you interested in learning more about observations with specific industry keywords? Get your FREE 483 Observation Report and you can quickly determine who has been hit with the same observations. Learn more here!]

Get your 483 Observation Report

483s Issued

DRUG FIRM: Aurobindo Pharma Ltd Unit 8

Aurobindo Pharma Ltd Unit 8 (Telangana, India) received a form 483 at the close of inspection on October 25, 2019. The firm manufactures APIs.

Observations include but are not limited to the following:

  • Cleaning validation is not adequate because it appears that not all equipment was considered during the validation. Also, the cleaning logbook was not maintained, so details of cleaning could not be verified.
  • Investigations were not complete or fully documented, particularly for OOS events.
  • Procedures are not established to determine when a reprocessed lot will be placed upon stability.
  • Electronic batch processing data for equipment is not maintained.

DRUG FIRM: Aurobindo Pharma Ltd Unit 5

Aurobindo Pharma Ltd Unit 5 (Telangana, India) received a form 483 at the close of inspection on October 28, 2019. The firm manufactures both sterile and non-sterile bulk drugs.

Observations include but are not limited to:

  • There is no scientific basis for invalidating OOS results.
  • Personnel activities during product filling do not fully protect drug substance. Personnel equipment, such as goggles, used in aseptic processing areas are not adequate to completely cover skin.
  • Process validation does not always include identification of parameters that should be monitored to ensure reproducible processing. 

DRUG FIRM: Aurobindo Pharma Ltd Unit 4

Aurobindo is having a very bad quarter. This is the fourth 483 from inspections since the end of September 2019 that has been made available.

This one, issued at the end of an inspection on November 13, 2019 is substantial at 37 pages. This inspection addressed Unit IV in Telangana, India for sterile drug manufacture. The inspection was conducted by five investigators including, Thomas Arista and Dipesh Shah, and lasted eight days. The 483 is heavily redacted but it’s worth reading. Here is an abbreviated approach to the 37 pages.

Observations include but are not limited to:

  • Observation #1 takes approximately 6 ½ pages and addresses aseptic technique as well as failures in how media fill simulations were conducted.
  • The EM sampling plan does not represent worst-case locations.
  • Equipment used to ensure adequate environmental control is not adequately maintained. This observation addresses a commitment made in response to an inspection in December 2018. There are 12 pages of heavily redacted examples.
  • Test methods, particularly for sterility testing, were not followed.
  • A Field Alert was not submitted for a customer complaint as it should have been within 3 days. 
  • At least 10 complaints for lack of effect were received and not adequately investigated. During the inspection, FDA noted that there seemed to be a trend that might implicate the API supplier for the product in question. The supplier was not named.
  • The computer system that identifies facility type alarms does not record the data from the event causing the alarm. The observation lists a collection of BMS type alarm events. Thus, investigation of what might have caused the alarm event is severely limited.
  • Laboratory analysts do not need to be trained on the tests they perform. Quality control checks are not conducted frequently enough to ensure that tests are being run correctly. 
  • QC lab worksheet documentation is not adequate. When multiple analysts contribute to an analysis only a single analyst is identified and only a single analyst signs the worksheet.

DRUG FIRM: Cadila Healthcare Limited

Zydus Cadila (Moraiya, India) received a 23-page, 14-observation form 483 issued in May 2019 at the end of the recent inspection. The firm received a warning letter on October 29, 2019. The FDA investigators included Thomas Arista and Justin Boyd.  The site manufactures sterile parenteral products.

Observations include but were not limited to:

  • Non-dedicated equipment that was labeled as ‘clean’ had visible residues.
  • Personnel aseptic practices were poor.
  • Not all media fill vials are subject to incubation.
  • Smoke studies did not demonstrate laminar airflow.
  • Adverse EM Personnel trends and other EM trends have not been the subject of effective corrective actions.
  • As-built diagrams for HVAC are not available at the company. It’s not clear that HVAC systems are adequate for aseptic processing areas.
  • SCADA data are not subject to backup.
  • Investigations into failures in periodic requalification aren’t accurate.
  • Tablet variability has not been assessed between batches and within batches.
  • Responsibilities of the Quality Unit are not fully followed.
  • Laboratory methods are not adequate; for example, extraneous peaks are not considered in raw materials received from vendors.

Compounding/Outsourcing Facilities

Athenex Pharma Solutions, LLC

Athenex Pharma Solutions, LLC (Clarence, NY) received a form 483 issued at the close of an inspection on August 29, 2019.

BSO LLC

BSO LLC (Lakewood, CO) received a form 483 at the close of inspection on September 20, 2019.

D&D Pharma LLC

D&D Pharma LLC (Noblesville, IN) received a form 483 at the close of inspection on July 17, 2019.

Downing Labs, LLC

Downing Labs, LLC (Dallas, TX) received a form 483 at the close of inspection on November 19, 2018.

InfuScience Inc

InfuScience Inc (Chantilly, VA) received a form 483 issued at the close of inspection on July 30, 2019.

Innoveix Pharmaceuticals

Innoveix Pharmaceuticals (Addison, TX) received a form 483 at the close of inspection on September 12, 2019.

Isorx, Corp.

Isorx, Corp. (Richmond, CA) received a form 483 based on the outcome of an inspection ending September 18, 2019.

Maimonides Medical Center-Pharmacy

Maimonides Medical Center-Pharmacy (Brooklyn, NY) received a form 483 at the close of inspection on July 29, 2019.

Medi-Fare Drug & Home Health Center Inc

Medi-Fare Drug & Home Health Center Inc (Blacksburg, SC) received an untitled letter on March 18, 2019.

Medoz Pharmacy of Pilk, Inc.

Medoz Pharmacy of Pilk, Inc. (Davenport, FL) received a form 483 at the close of inspection ending August 9, 2019.

Pacifica Pharmacy

Pacifica Pharmacy (Torrance, CA) received a form 483 issued at the close of inspection on September 9, 2019.

Govzilla Store’s Most Purchased Individual 483s

483 Accupac Mainland Nov 2017

483 Biocon Bangalore Mar 2018

483 CoreRx Clearwater Nov 2016

483 Dr. Reddy’s Labs Ranashthalam Mandal, Srikakulam Jan 2019

483 Jubilant Generics Mysore Dec 2018

483 Merck Sharp & Dohme, a subsidiary of Merck Elkton Oct 2018

483 Mylan Labs Limited (Unit 8) Vizianagaram Dec 2018

483 Mylan Teoranta Inverin Feb 2018

483 Strides Pharma Science Bangalore May 2019

483 WuXi AppTec Saint Paul Sep 2019

[NOTE: With a 483 Observation Report, you can quickly determine if there’s a citation trend you should be aware of.  Learn more here!]

Get your 483 Observation Report

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

June 29, 1:30 p.m. EST

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.